Research progress on beta-blockers in the treatment of sepsis-induced cardiomyopathy: A mini review
Open Access
- 18 January 2026
- journal article
- Published by SAGE Publications in Sage Open Medicine
- Vol. 14
Abstract
Sepsis-induced cardiomyopathy (SCM), a frequent complication of septic shock with mortality exceeding 40%, arises from catecholamine-driven cardiotoxicity, sympathetic hyperactivity, and inflammation-mediated biventricular dysfunction. Short-acting β₁-blockers (esmolol, landiolol) offer a targeted therapeutic approach by reducing heart rate (target: 80–95 bpm), myocardial oxygen demand, and proinflammatory cytokines while improving diastolic perfusion—leveraging ultra-short half-lives (t₁/₂ = 4–9 min) for rapid reversibility during instability. Clinical evidence remains divergent: a landmark single-center RCT demonstrated significant 28-day mortality reduction (49.4% vs 80.5%; p < 0.001), improved hemodynamics, and reduced vasopressor requirements in hemodynamically stabilized patients, whereas premature termination of a multicenter trial revealed harm (increased vasopressor needs, mortality trend) when initiated during persistent hypoperfusion (lactate > 2 mmol/L). Current limitations include heterogeneous trial designs, small samples, and undefined benefiting phenotypes. Thus, cautious short-acting β-blockade is supported only for selected SCM patients with hemodynamic stability (MAP ⩾65 mmHg, normalized lactate, LVEF >35%), necessitating future precision trials with AI phenotyping to guide mechanism-targeted application.Keywords
Funding Information
- Sanming Project of Medicinein Shenzhen (SZSM202206006)
This publication has 31 references indexed in Scilit:
- Beta-Adrenergic Blockade in Critical IllnessFrontiers in Pharmacology, 2021
- Sepsis—Pathophysiology and Therapeutic ConceptsFrontiers in Medicine, 2021
- Premorbid β1-selective (but not non-selective) β-blocker exposure reduces intensive care unit mortality among septic patientsJournal of Intensive Care, 2021
- Pathophysiology of sepsis-induced cardiomyopathyNature Reviews Cardiology, 2021
- Microvascular dysfunction in septic and dengue shock: Pathophysiology and implications for clinical managementGlobal Cardiology Science and Practice, 2020
- Ultra-Short–Acting β-Blockers (Esmolol and Landiolol) in the Perioperative Period and in Critically Ill PatientsJournal of Cardiothoracic and Vascular Anesthesia, 2018
- The β-Blocker Esmolol Restores the Vascular Waterfall Phenomenon After Acute Endotoxemia*Critical Care Medicine, 2017
- Effect of Heart Rate Control With Esmolol on Hemodynamic and Clinical Outcomes in Patients With Septic ShockJAMA, 2013
- Beta-block the septic heartCritical Care Medicine, 2010
- Myocardial and vascular adrenergic alterations in a rat model of endotoxin shockCritical Care Medicine, 1997